Skip to main content

Length of Ischemic Time Is Critical for Accurate Determination of Homologous Recombination Capacity by Immunofluorescence Staining in Ovarian Cancer Formalin-Fixed Paraffin-Embedded Samples

In brief

Delayed tissue processing lowers ovarian cancer HR scores and creates false deficiency calls

In ovarian high-grade serous cancer samples, prolonged time before processing reduced the RAD51 signal and caused some tumors to be misclassified as homologous recombination deficient. Other tested handling conditions had no significant effect, and results were consistent across tumor regions. Functional HR testing may be unreliable when archival sample handling times are unknown, which could affect patient selection for PARP inhibitors.

Journal
Archives of pathology & laboratory medicine (Q1)
Published
17 November 2026
Study design
Prospective / inception cohort
Evidence level
Level 2, Moderate (CEBM 2b)
Authors
Ezgi Karagöz, Sanna Pikkusaari, Minna R Eriksson, Srividhya Sundaresan, Matilda Salko, Jaana Oikkonen, et al.
PMID
43042964
DOI
10.5858/arpa.2025-0479-OA

Why clinicians should know about it

Abstract

CONTEXT.—: Tubo-ovarian high-grade serous carcinomas (HGSC) that are deficient in homologous recombination (HR) are more sensitive to poly ADP-ribose polymerase (PARP) inhibitors than their HR-proficient counterparts. To target PARP inhibitors to the right patients, HR status must be accurately determined. Functional HR (fHR) assays, which assess HR status by quantifying RAD51, are promising approaches for identifying HR-deficient cases. However, these tests have yet to be optimized for pre-analytical variables and tissue properties that may impact RAD51 quantification. OBJECTIVE.—: To establish how typical pre-analytical variables (ischemic time, formalin fixation, and ethanol storage) and tissue-level necrosis and hypoxia affect read-outs of fHR capacity, with systematic evaluation of prolonged ischemic time. Additionally, biological (intra-tumor) variation in fHR measurements was assessed. DESIGN.—: The immunofluorescence-based fHR assay was performed on a retrospective and a prospectively collected cohort of formalin-fixed paraffin-embedded HGSC specimens with varying pre-analytical and tissue-level conditions. Intra-tumor variation in fHR capacity was assessed in multiple tumor areas and independent tumor pieces. RESULTS.—: Prolonged ischemic time led to a substantial reduction in nuclear RAD51 signal, resulting in lower fHR scores and false fHR deficiency calls. The other examined variables did not significantly impact fHR scores. Intra-tumor variation in fHR scores was low, and the fHR category, when determined from different regions of the same tumor, remained unchanged. CONCLUSIONS.—: Prolonged ischemic time adversely affects fHR assay performance, highlighting the importance of monitoring and documenting sample handling processes, particularly in HGSC, and warrants caution when interpreting fHR results from archival tumor material for which such information is unavailable.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.